Processing

Please wait...

Settings

Settings

Goto Application

1. CN1354747 - 2-amino-4H-3.1-benzoxazinone-4-keto derivatives for treatment of obesity

Office
China
Application Number 00803621.7
Application Date 06.01.2000
Publication Number 1354747
Publication Date 19.06.2002
Grant Number 100480245
Grant Date 22.04.2009
Publication Kind C
IPC
C07D 265/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
041,3-Oxazines; Hydrogenated 1,3-oxazines
12condensed with carbocyclic rings or ring systems
14condensed with one six-membered ring
24with hetero atoms directly attached in positions 2 and 4
26Two oxygen atoms, e.g. isatoic anhydride
C07C 271/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
271Derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups
06Esters of carbamic acids
08having oxygen atoms of carbamate groups bound to acyclic carbon atoms
26with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
28to a carbon atom of a non-condensed six-membered aromatic ring
A61K 31/536
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
536ortho- or peri-condensed with carbocyclic ring systems
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
CPC
C07C 271/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
271Derivatives of carbamic acids, i.e. compounds containing any of the groups , the nitrogen atom not being part of nitro or nitroso groups
06Esters of carbamic acids
08having oxygen atoms of carbamate groups bound to acyclic carbon atoms
26with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
28to a carbon atom of a non-condensed six-membered aromatic ring
C07C 271/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
271Derivatives of carbamic acids, i.e. compounds containing any of the groups , the nitrogen atom not being part of nitro or nitroso groups
06Esters of carbamic acids
40having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
58with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
C07D 265/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
041,3-Oxazines; Hydrogenated 1,3-oxazines
12condensed with carbocyclic rings or ring systems
14condensed with one six-membered ring
24with hetero atoms directly attached in positions 2 and 4
26Two oxygen atoms, e.g. isatoic anhydride
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
Applicants Alizyme Therapeutics Ltd.
阿利茨默治疗学有限公司
Inventors H.F. Hodson
H·F·胡德森
R. Downham
R·唐恩哈姆
T.J. Mitchell
T·J·米歇尔
B·J·卡尔
C·R·敦克
R·M·J·帕尔默
Agents guo jianxin
中国国际贸易促进委员会专利商标事务所
Priority Data 9900416.0 08.01.1999 GB
Title
(EN) 2-amino-4H-3.1-benzoxazinone-4-keto derivatives for treatment of obesity
(ZH) 治疗肥胖症的2-氨基-4H-3,1-苯并嗪-4-酮衍生物
Abstract
(EN) The use of a compound comprising formula(I)or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyze the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula(I), to processes for preparing them and pharmaceutical compositions containing them. In formula(I)A is a 6-membered aromatic or heteroaromatic ring; and R<1> is a branched or unbranched alkyl(optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
(ZH)

包括式(I)的化合物或其盐、酯、酰胺或前体药物在抑制一种酶中的应用,所述酶的优选作用模式是催化酯官能度的水解,例如,控制和抑制产品和工艺中不需要的酶。所述化合物还适用于医药,例如,用于治疗肥胖症和相关的病况。本发明还涉及式(I)中的新型化合物,涉及制备它们的方法和包含它们的药物组合物。在式(I)中,A是6元芳环或杂芳环;而且R1是支化或非支化的烷基(任选间隔一个或多个氧原子),烯基,炔基,环烷基,环烯基,芳基,芳烷基,还原芳烷基,芳烯基,杂芳基,杂芳烷基,杂芳烯基,还原芳基,还原杂芳基,还原杂芳烷基或任何上述基的取代衍生物。


Related patent documents
SGSG2001041441This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NO20013380This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.